Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation
Saïd Bendahhou, … , Stephen G. Waxman, Louis J. Ptácek
Saïd Bendahhou, … , Stephen G. Waxman, Louis J. Ptácek
Published August 1, 2000
Citation Information: J Clin Invest. 2000;106(3):431-438. https://doi.org/10.1172/JCI9654.
View: Text | PDF
Article

A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation

  • Text
  • PDF
Abstract

Hyperkalemic periodic paralysis (HyperKPP) is an autosomal dominant skeletal muscle disorder caused by single mutations in the SCN4A gene, encoding the human skeletal muscle voltage-gated Na+ channel. We have now identified one allele with two novel mutations occurring simultaneously in the SCN4A gene. These mutations are found in two distinct families that had symptoms of periodic paralysis and malignant hyperthermia susceptibility. The two nucleotide transitions predict phenylalanine 1490→leucine and methionine 1493→isoleucine changes located in the transmembrane segment S5 in the fourth repeat of the α-subunit Na+ channel. Surprisingly, this mutation did not affect fast inactivation parameters. The only defect produced by the double mutant (F1490L-M1493I, expressed in human embryonic kidney 293 cells) is an enhancement of slow inactivation, a unique behavior not seen in the 24 other disease-causing mutations. The behavior observed in these mutant channels demonstrates that manifestation of HyperKPP does not necessarily require disruption of slow inactivation. Our findings may also shed light on the molecular determinants and mechanism of Na+ channel slow inactivation and help clarify the relationship between Na+ channel defects and the long-term paralytic attacks experienced by patients with HyperKPP.

Authors

Saïd Bendahhou, Theodore R. Cummins, Angelika F. Hahn, Sylvie Langlois, Stephen G. Waxman, Louis J. Ptácek

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Enhancement of slow inactivation in the F1490L-M1493I channels. (a) Stea...
Enhancement of slow inactivation in the F1490L-M1493I channels. (a) Steady-state slow inactivation in hSkM1 (filled circles; n = 23), F1490L (filled diamonds; n = 9), M1493I (filled squares; n = 9), and F1490L-M1493I (open circles; n = 18) channels. The first step consists of holding the cells at potentials ranging from –130 to 10 mV in 10-mV steps for 50 seconds. A 30-millisecond recovery pulse to –100 mV and a 20-millisecond test pulse to –10 mV were given before the holding potential was incremented again. The holding potential was incremented by 10 mV immediately after each recovery pulse/test pulse sequence. We term this protocol sequential because the channels are not allowed to recover from slow inactivation for each test pulse; the expectation is that the sequential changes in holding potential will mimic changes in holding potential of longer durations. The short hyperpolarizing recovery pulses can be used to remove fast inactivation just before a test pulse to measure slow inactivation (31). The peak current elicited by the test pulse to –10 mV was plotted as a fraction of the maximum current. (b) A greater fraction of F1490L-M1493I current than WT current is slow inactivated at –60 mV. Cells were held for 50 seconds at –60 mV, allowed to recover for 30 millisecond at –100 mV, and then depolarized to –10 mV to determine the fraction of channels that are slow inactivated. For comparison, the total current available from a holding potential of –100 mV is also shown for WT and F1490L-M1493I channels. (c) Development of slow inactivation is shown to be faster for the F1490L-M1493I (open circles; n = 5) than for the WT channels (filled circles; n = 5). Cells were held at –100 mV for an increasing conditioning time. (d) Normalized Na+ current in representative WT (filled circles; n = 9), F1490L (filled diamonds; n = 8), M1493I (filled squares; n = 7), and F1490L-M1493I (open circles; n = 8) cells recovering from slow inactivation (conditioning pulse is –50 mV). The time axis is logarithmic. The recovery protocol required about 45 minutes to complete and had two phases: short recovery times were obtained with individual recovery pulses, and long recovery times were obtained in a continuous recording.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts